Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175623-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $79.90 | |
Ab175623-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $379.90 | |
Ab175623-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $989.90 | |
Ab175623-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,589.90 |
Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Ozoralizumab (anti-TNF-alpha&HSA) - Primary antibody, specific to TNF; ALB |
---|---|
Synonyms | ATN-103;PF-5230896 |
Specifications & Purity | Carrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, ExactAb™, ≥90%(SDS-PAGE&SEC), Lot by Lot |
Specificity | TNF; ALB |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | INHIBITOR |
Mechanism of action | INHIBITOR of TNF-alpha inhibitor |
Product Description |
Ozoralizumab (anti-TNF-alpha&HSA) is an anti-TNFα humanized antibody. Ozoralizumab (anti-TNF-alpha&HSA) is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab (anti-TNF-alpha&HSA) can be used in research of arthritis. |
SDS-PAGE | 38.44 kDa |
---|---|
Purification Method | Protein A purified |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1167985-17-2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 382 |
---|
Enter Lot Number to search for COA:
1. Kratz F, Elsadek B. (2012) Clinical impact of serum proteins on drug delivery.. J Control Release, 161 (2): (429-45). [PMID:22155554] |